Search Prime Grants

R01AG092960

Project Grant

Overview

Grant Description
Proteomic signatures of delirium and long-term cognitive decline in older cardiac surgical patients - Project summary

Postoperative delirium following cardiac surgery is characterized by sudden onset confusion and inattention.

It incurs substantial costs and can lead to long-term cognitive decline, including Alzheimer’s disease and related dementias (AD/ADRD).

Enhancing our ability to identify at-risk patients before surgery and implementing targeted interventions based on underlying pathophysiology is important.

In our DEXACET trial, which demonstrated the effectiveness of intravenous acetaminophen in reducing postoperative delirium after cardiac surgery (JAMA 2019), we conducted a systematic analysis of plasma samples collected at baseline and on postoperative day 2.

Utilizing the SOMASCAN platform V 3.2 to analyze 1305 proteins, we developed a multivariable risk model for predicting preoperative delirium, identifying three novel proteins (TIMP1, ANGPT2, and CCL5), and highlighting older age and female gender as additional risk factors.

These proteins indicate disruptions in immune function, inflammatory response, and neovascularization regulation.

Furthermore, insights from proteomics research in the SAGES I & II cohorts suggest a systemic pre-inflammatory state predisposes to a hyperactive inflammatory response to major surgery, resulting in delirium in those with vulnerable brains.

The DEXACET trial led to a successful NIA funded PANDORA trial to examine the impact of scheduled 6-hourly intravenous acetaminophen over 48 hours in 900 cardiac surgical patients (760 recruited, May 2024 from 12 centers).

Leveraging on the banked plasma specimens from this ongoing trial, we will use a state-of-the-art SOMASCAN V5.0 proteomics platform that measures 11,000 proteins to derive (N=300, placebo group) and validate (N=remaining 150 placebo group patients) a delirium protein signature for cardiac surgery (Aim 1A).

The SOMASCAN-derived top 10 proteins will be independently validated with standard antibody-based methods (ELLA) in all 450 placebo group patients (Aim 1C).

This model will then be probed with the acetaminophen group (N=450, Aim 1B).

We will combine proteins from the AD/ADRD and aging proteomic signatures, along with additional proteins from the 11,000 protein SOMASCAN V5.0 covering many biological pathways, for a deep etiopathological characterization of the plasma proteome for delirium and 12-month cognitive decline in the PANDORA cohort (Aim 2).

Furthermore, leveraging data from the NIA-funded SAGES I (N=560) & II (N=420) cohorts, we will independently validate the risk model developed in Aim 1 (Aim 3A) and explore similarities and differences in delirium mechanisms between cardiac and non-cardiac surgeries (Aim 3B).

This comprehensive approach aims to provide new insights into the molecular mechanisms underlying delirium risk, pathogenesis, and its association with 12-month cognitive decline.

Ultimately, the project seeks to develop accurate blood-based biomarkers for preoperative delirium risk prediction, prognostication of cognitive decline following delirium, and lay the groundwork for targeted interventions to improve outcomes in older adults at risk of delirium following cardiac surgery.
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM; TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT; TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT; AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS; TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS; TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT; AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Place of Performance
Boston, Massachusetts 022155400 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the total obligations have increased 100% from $1,631,690 to $3,266,117.
Beth Israel Deaconess Medical Center was awarded Delirium Proteomic Signature Study in Cardiac Surgery Patients Project Grant R01AG092960 worth $3,266,117 from National Institute on Aging in June 2025 with work to be completed primarily in Boston Massachusetts United States. The grant has a duration of 4 years 9 months and was awarded through assistance program 93.866 Aging Research. The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).

Status
(Ongoing)

Last Modified 4/20/26

Period of Performance
6/15/25
Start Date
3/31/30
End Date
20.0% Complete

Funding Split
$3.3M
Federal Obligation
$0.0
Non-Federal Obligation
$3.3M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R01AG092960

Transaction History

Modifications to R01AG092960

Additional Detail

Award ID FAIN
R01AG092960
SAI Number
R01AG092960-1431120636
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NN00 NIH National Insitute on Aging
Awardee UEI
C1CPANL3EWK4
Awardee CAGE
4B998
Performance District
MA-07
Senators
Edward Markey
Elizabeth Warren
Modified: 4/20/26